Will ABBV's Q2 earnings streak continue in 2025?

**ABBV's Q2 earnings streak is likely to continue in 2025**, based on several key factors: 1. **Strong Portfolio Performance**: AbbVie's immunology drugs, Humira, Skyrizi, and Rinvoq, have shown strong sales performance, with Humira's U.S. market share remaining over 80% despite biosimilar competition. Skyrizi and Rinvoq have surpassed expectations with global sales of $2.73 billion and $1.43 billion, respectively. 2. **Diverse Revenue Streams**: AbbVie's diversified portfolio and recent acquisitions, such as Cerevel, indicate a strategic focus on maintaining revenue growth across multiple therapeutic areas. This diversification reduces dependence on any single product, enhancing resilience against future challenges. 3. **Financial Outlook and Analyst Confidence**: The company has raised its FY24 forecast, reflecting confidence in its performance, with adjusted diluted EPS expected to be between $10.71 and $10.91 per share. Analysts maintain a bullish outlook with a Strong Buy consensus rating, suggesting expectations for continued growth. 4. **Innovation and Pipeline**: AbbVie's ongoing innovation in R&D and a robust pipeline are poised to support future growth, despite the challenges posed by the expiration of the Humira patent. The company has a history of substantial R&D investments, which are likely to yield new medicines contributing to long-term growth. 5. **Market Position and Growth Prospects**: Despite the impact of the IRA on Humira and Imbruvica, AbbVie is well-positioned for long-term growth, driven by key growth drivers such as Skyrizi and Rinvoq, and the potential for strong performance across its diversified portfolio. In conclusion, while challenges exist, particularly regarding the impact of patent expirations and market dynamics, AbbVie's strong portfolio, strategic positioning, and positive financial outlook suggest that its Q2 earnings streak could continue in 2025.